MX2023012039A - Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos. - Google Patents
Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos.Info
- Publication number
- MX2023012039A MX2023012039A MX2023012039A MX2023012039A MX2023012039A MX 2023012039 A MX2023012039 A MX 2023012039A MX 2023012039 A MX2023012039 A MX 2023012039A MX 2023012039 A MX2023012039 A MX 2023012039A MX 2023012039 A MX2023012039 A MX 2023012039A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- parp inhibitors
- formula
- fused bicyclic
- substituted fused
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/80—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110392892 | 2021-04-12 | ||
| CN202110707739 | 2021-06-24 | ||
| CN202111065912 | 2021-09-10 | ||
| PCT/CN2022/086311 WO2022218296A1 (en) | 2021-04-12 | 2022-04-12 | Substituted fused bicyclic compounds as parp inhibitors and the use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023012039A true MX2023012039A (es) | 2024-03-05 |
Family
ID=83640149
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023012039A MX2023012039A (es) | 2021-04-12 | 2022-04-12 | Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos. |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240208969A1 (https=) |
| EP (1) | EP4326713A4 (https=) |
| JP (1) | JP2024513538A (https=) |
| KR (1) | KR20240009929A (https=) |
| CN (3) | CN117653636B (https=) |
| CA (1) | CA3216489A1 (https=) |
| MX (1) | MX2023012039A (https=) |
| WO (1) | WO2022218296A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024050370A1 (en) * | 2022-08-30 | 2024-03-07 | 1Cbio, Inc. | Heterocyclic compounds and methods of use thereof |
| KR20250103668A (ko) * | 2022-11-10 | 2025-07-07 | 치아타이 티안큉 파마수티컬 그룹 주식회사 | 축합 이환 화합물 |
| TW202506680A (zh) * | 2023-04-28 | 2025-02-16 | 美商思諾維新醫藥公司 | 作為ｐａｒｐ１抑制劑之雜環化合物 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998018781A2 (en) * | 1996-10-28 | 1998-05-07 | Versicor, Inc. | Fused 2,4-pyrimidinedione combinatorial libraries, their preparation and the use of fused 2,4-pyrimidinediones derivatives as antimicrobial agents |
| JP2001302515A (ja) * | 2000-04-18 | 2001-10-31 | Sumitomo Pharmaceut Co Ltd | ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤 |
| JP2002284699A (ja) * | 2001-03-28 | 2002-10-03 | Sumitomo Pharmaceut Co Ltd | 視細胞変性疾患治療剤 |
| CN1918151A (zh) * | 2003-12-19 | 2007-02-21 | 伊莱利利公司 | 三环甾类激素核受体调节剂 |
| EA011552B1 (ru) * | 2004-06-30 | 2009-04-28 | Янссен Фармацевтика Н.В. | Производные хиназолиндиона в качестве ингибиторов parp |
| MX2007010068A (es) * | 2005-02-16 | 2007-10-10 | Schering Corp | Piperazino-piperidinas con actividad antagonista de cxcr3. |
| JP2007137818A (ja) * | 2005-11-17 | 2007-06-07 | Taisho Pharmaceut Co Ltd | ８−ヒドロキシ−２，４（１ｈ，３ｈ）−キナゾリンジオン誘導体 |
| US8404713B2 (en) * | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| WO2009086303A2 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| ES2367760T3 (es) * | 2008-03-27 | 2011-11-08 | Janssen Pharmaceutica, N.V. | Derivados de quinazolinona como inhibidores de la polimerización de la tubulina. |
| JP5744019B2 (ja) * | 2009-07-14 | 2015-07-01 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | 選択的ｐａｒｐ−１阻害を有する３−オキソ−２，３−ジヒドロ−１ｈ−イソインドール−４−カルボキサミド |
| WO2011021678A1 (ja) * | 2009-08-21 | 2011-02-24 | 武田薬品工業株式会社 | 縮合複素環化合物 |
| JP2012184205A (ja) * | 2011-03-08 | 2012-09-27 | Dainippon Sumitomo Pharma Co Ltd | ２−アミノ置換８−オキソジヒドロプリン誘導体 |
| CA2829123C (en) * | 2011-03-14 | 2016-04-12 | Eternity Bioscience Inc. | Quinazolinediones and their use |
| CN102731416A (zh) * | 2011-04-01 | 2012-10-17 | 南京英派药业有限公司 | 1-(芳基甲基)-喹唑啉-2，4-二酮作为parp抑制剂及其应用 |
| TWI527800B (zh) * | 2011-04-01 | 2016-04-01 | 南京英派藥業有限公司 | 作為聚（二磷酸腺苷酸－核醣）聚合酶（ｐａｒｐ）之抑制劑之１－（芳基甲基）喹唑啉－２，４（１ｈ，３ｈ）－二酮及其應用 |
| EP2913330A1 (en) * | 2014-02-27 | 2015-09-02 | Laboratoire Biodim | Condensed derivatives of imidazole useful as pharmaceuticals |
| CN104892589A (zh) * | 2014-03-07 | 2015-09-09 | 中国科学院上海药物研究所 | 一类杂环化合物、其制备方法和用途 |
| CN109563051B (zh) * | 2016-08-22 | 2024-06-11 | 南京明德新药研发有限公司 | 作为pde4抑制剂的并环类化合物 |
| AU2017317123B9 (en) * | 2016-08-22 | 2021-11-25 | Medshine Discovery Inc. | PDE4 inhibitor |
| WO2018112842A1 (en) * | 2016-12-22 | 2018-06-28 | Merck Sharp & Dohme Corp. | 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor |
| WO2018165615A1 (en) * | 2017-03-09 | 2018-09-13 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Parp-1 and methods of use thereof |
| SI3999506T1 (sl) * | 2019-07-19 | 2025-06-30 | Astrazeneca Ab | Zaviralci PARP1 |
-
2022
- 2022-04-12 EP EP22787519.2A patent/EP4326713A4/en active Pending
- 2022-04-12 US US18/554,980 patent/US20240208969A1/en active Pending
- 2022-04-12 KR KR1020237037924A patent/KR20240009929A/ko active Pending
- 2022-04-12 WO PCT/CN2022/086311 patent/WO2022218296A1/en not_active Ceased
- 2022-04-12 CN CN202311660486.7A patent/CN117653636B/zh active Active
- 2022-04-12 CN CN202280011128.0A patent/CN116783181B/zh active Active
- 2022-04-12 CN CN202610252591.4A patent/CN121800782A/zh active Pending
- 2022-04-12 JP JP2024505487A patent/JP2024513538A/ja active Pending
- 2022-04-12 MX MX2023012039A patent/MX2023012039A/es unknown
- 2022-04-12 CA CA3216489A patent/CA3216489A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116783181B (zh) | 2026-01-30 |
| CN117653636A (zh) | 2024-03-08 |
| EP4326713A4 (en) | 2025-03-19 |
| JP2024513538A (ja) | 2024-03-25 |
| WO2022218296A1 (en) | 2022-10-20 |
| EP4326713A1 (en) | 2024-02-28 |
| KR20240009929A (ko) | 2024-01-23 |
| CA3216489A1 (en) | 2022-10-20 |
| CN116783181A (zh) | 2023-09-19 |
| CN121800782A (zh) | 2026-04-07 |
| US20240208969A1 (en) | 2024-06-27 |
| CN117653636B (zh) | 2024-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024002425A (es) | Compuestos tricíclicos sustituidos como inhibidores de parp y uso de estos. | |
| GEAP202616866A (en) | 2-azabicyclo[2.2.1]heptane kras inhibitors | |
| CR20230310A (es) | Inhibidores de prmt5 | |
| MX2023009222A (es) | Inhibidores tricíclicos-amido-bicíclicos de prmt5. | |
| MX2022008066A (es) | Compuestos triciclicos sustituidos. | |
| MX2022015703A (es) | Compuestos para el tratamiento de enfermedades y trastornos asociados a braf. | |
| MX2025011899A (es) | Compuestos de pirido[4,3-d]pirimidina | |
| GEP20237561B (en) | Protein tyrosine phosphatase inhibitors | |
| MX2023012039A (es) | Compuestos bicíclicos fusionados sustituidos como inhibidores de parp y uso de estos. | |
| GEAP202416135A (en) | 2-oxoimidazolidine-4-carboxamides as nav1.8 inhibitors | |
| UA86614C2 (ru) | Соединение, которое имеет активность ингибитора киназ, фармацевтическая композиция, которая включает указанное соединение, и их применение для приготовления лекарственного препарата | |
| MX2025003995A (es) | Nuevo compuesto heterociclilo biciclico y uso de este | |
| EA200702339A1 (ru) | Замещенные амидные производные в качестве ингибиторов протеинкиназы | |
| MX2020010805A (es) | Inhibidores de bcl6. | |
| SE0202462D0 (sv) | Novel use | |
| MX2022015531A (es) | Derivado de piridina-pirimidina, metodo de preparacion y uso farmaceutico del mismo. | |
| ZA202404839B (en) | Tricyclic fused heterocyclic pde3/4 dual inhibitor and use thereof | |
| MX2022013946A (es) | Antagonistas del receptor de adenosina a2a. | |
| PH12021550554A1 (en) | N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamides useful as ccr6 inhibitors | |
| WO2020247298A3 (en) | 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof | |
| MY195576A (en) | Novel Amino-Imidazopyridine Derivatives as Janus Kinase Inhibitors and Pharmaceutical use Thereof | |
| EA201992090A1 (ru) | ДЕЙТЕРИРОВАННЫЕ СОЕДИНЕНИЯ ИМИДАЗО[4,5-c]ХИНОЛИН-2-ОНА И ИХ ПРИМЕНЕНИЕ В ЛЕЧЕНИИ РАКА | |
| SA522441650B1 (ar) | مثبطات فوسفوينوسيتيد 3-كيناز الموضعية | |
| MX2023006881A (es) | Antagonistas del receptor de adenosina a2a. | |
| GEAP202516737A (en) | Compounds for treating cancer |